Rethinking Glucocorticoids as First-Line Therapy in IgG4-RD

In "Rethinking Glucocorticoids as First-Line Therapy in IgG4-RD," Dr. Katz challenges a long-standing treatment convention.

Dr. Katz acknowledges that clinicians answer this question differently. Around the world, glucocorticoids are considered the standard first-line treatment for IgG4-related disease. He does not view them that way. Many patients have risk factors for glucocorticoid toxicity. Most patients treated with glucocorticoids alone relapse soon after withdrawal. For these reasons, he now uses B-cell depletion as first-line treatment for the vast majority of patients.

For Dr. Katz, adding glucocorticoids depends on how urgently disease control is needed. In patients with urgent manifestations, he may give a short 2- to 3-month course while B-cell depletion begins to work. He reserves glucocorticoid monotherapy for a small subset with mild disease. One example is mildly symptomatic disease limited to the head and neck, without relapse risk factors. A few weeks of prednisone may control the disease for a long time. In that setting, a short steroid course may be safer than prolonged B-cell depletion.

Dr. Culver asks about tapering schedules. Dr. Katz distinguishes between using glucocorticoids as a diagnostic test and using them as treatment. For a patient with a pancreatic mass, he gives prednisone 40 mg daily for 1 month. He then repeats imaging to confirm that the mass has shrunk. He avoids deviating from that dose. If a lower dose fails to shrink the mass, clinicians cannot tell whether the dose was inadequate or the diagnosis wrong.

When glucocorticoids are used purely for disease control in severe cases, he starts at 40 mg. Rarely, he uses 60 mg very briefly. He aims to reach 20 mg within about a month, then tapers over roughly another 2 months. He notes that this schedule closely mirrors the approach used in recent clinical trials. Dr. Culver summarizes the goal as a taper of no more than about 3 months.

Our next episode, "Glucocorticoid Toxicity in IgG4-RD: Why Shorter Steroid Courses Matter," turns to the cumulative harms of glucocorticoids in an older population with frequent comorbidities.